@article{22323c4fb9e14c3dae75e383f10ca6b9,
title = "Core outcome measures for chronic pain clinical trials: IMMPACT recommendations",
keywords = "Adverse events, Assessment, Chronic pain, Clinical trials, Emotional functioning, Global ratings, Health-related quality of life, Outcomes, Physical functioning, Randomized controlled trials",
author = "Dworkin, {Robert H.} and Turk, {Dennis C.} and Farrar, {John T.} and Haythornthwaite, {Jennifer A.} and Jensen, {Mark P.} and Katz, {Nathaniel P.} and Kerns, {Robert D.} and Gerold Stucki and Allen, {Robert R.} and Nicholas Bellamy and Carr, {Daniel B.} and Julie Chandler and Penney Cowan and Raymond Dionne and Galer, {Bradley S.} and Sharon Hertz and Jadad, {Alejandro R.} and Kramer, {Lynn D.} and Manning, {Donald C.} and Susan Martin and McCormick, {Cynthia G.} and McDermott, {Michael P.} and Patrick McGrath and Steve Quessy and Rappaport, {Bob A.} and Wendye Robbins and Robinson, {James P.} and Margaret Rothman and Royal, {Mike A.} and Lee Simon and Stauffer, {Joseph W.} and Wendy Stein and Jane Tollett and Joachim Wernicke and James Witter",
note = "Funding Information: The authors thank Charles S. Cleeland, PhD, for his comments on a preliminary draft of this article, and Paul J. Lambiase and Mary Gleichauf for their invaluable assistance. Abbott Laboratories, AstraZeneca, Elan Pharmaceuticals, Eli Lilly & Co., Endo Pharmaceuticals Inc., GlaxoSmithKline, Johnson and Johnson, Merck & Co., NeurogesX, Novartis Pharmaceuticals, Pfizer, and Purdue Pharma provided unrestricted grants to the University of Rochester Office of Professional Education to support the consensus meeting. ",
year = "2005",
month = jan,
doi = "10.1016/j.pain.2004.09.012",
language = "English (US)",
volume = "113",
pages = "9--19",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "1-2",
}